AI-generated · cited to primary sources · not investment advice
Alkem Lab (539523) Nov 2025 Filing Analysis
Does management do what it says?
International sales grew by 26.6% Y-o-Y in Q3, surpassing the high-teens guidance. (2 exceeded across 2 tracked commitments)
“We are expecting that looking at even the second half projections, we should be easily upwards close to around high teens of 20% kind of growth from the non-U.S. markets.”
R&D expenses for the quarter were 3.7%, which is slightly below the guided range but shows disciplined spending relative to the 4-5% target. (2 met across 2 tracked commitments)
“So I think it's more of a phasing thing, and we expect the R&D to be within 4% to 5% -- and I think we should get them.”
The company reported an EBITDA margin of 22.2% for Q3 FY26, which is significantly higher than the full-year guidance range. (2 exceeded, 1 revised, 1 met, 1 missed across 5 tracked commitments)
“And even from the EBITDA guidance perspective, I see somewhere between 19.5% to 20% should be our EBITDA for the full year.”
U.S. CDMO plant expected to reach breakeven in 12 to 18 months. — target: Breakeven
“12 to 18 months. It has just started operational in this quarter. And then 12 to 18 months, we should be reaching the breakeven.”
See the full cited Management analysis of Alkem Lab
Where does growth come from?
Alkem is aggressively pursuing the GLP-1 (diabetes/weight loss) market, having completed clinical trials for the Indian market and awaiting final marketing authorization. They expect to be among the first players to launch upon patent expiry. (2 new trend across 2 signals)
“So I think our India application, our CT for diabetes indication is already completed... We are very hopeful that very shortly, we will get the approval for GLP-1.”
See the full cited Future Growth analysis of Alkem Lab
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.